Advice to Community Oncologists Treating with Bispecifics

EP: 1.Case Presentation: A 63-Year-Old Patient with Relapsed-Refractory (R/R) Multiple Myeloma

EP: 2.MonumenTAL-1 and Bispecifics Under Development for The Treatment of R/R Multiple Myeloma

EP: 3.MoumenTAL-1: Management of Adverse Events and Health-Related Quality of Life Outcomes

EP: 4.Comparing Bispecifics, ADCs, and CAR T-Cell Therapy for the Treatment of MM

Now Viewing

EP: 5.Advice to Community Oncologists Treating with Bispecifics

Case: A 63-Year-Old Man with R/R Multiple Myeloma

Clinical Presentation:

Patient AG is a 63 y/o man.

• PMH: Diabetes, Hypertension
• SMH: Does not smoke or drink alcohol
• In October 2018, AG was admitted from clinic with hypercalcemia (Ca 13.7) and anemia (Hb 10.6) after a right pathologic hip fracture.

Clinical Workup and Diagnosis:

• Calcium: 11.7 mg/dL
• M-protein, 2.1 g/dL
• Hemoglobin: 11.2 g/dL
• Elevated LDH
• Albumin, 2.7 g/dL
• SCr, 1.3 mg/dL
• Bone marrow biopsy confirms 25% clonal plasma cells, FISH del(17p)
• PET-CT confirms osteolytic bone lesions in both hips; SF diagnosed with IgG kappa multiple myeloma

Disease Relapse and Treatments:

• AG was initiated on VRd (bortezomib, lenalidomide, and low-dose dexamethasone) in frontline setting
• He subsequently relapsed and progressed on 3 lines of therapy including belantamab mafodotin
• He was then enrolled in a clinical trial and started on treatment with the bispecific antibody, talquetamab following four prior lines of therapy
• Talquetamab was started at a dose of 0.4 mg/kg every week SC